ArticleFrontiers in pharmacology2025
Benzodiazepine use in Spain: risks and perspectives on the current situation and proposals for their rational use.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prescription of Psychotropic Drugs for Chronic Insomnia in Primary Care.Journal of sleep research · 2026Observational
- A 21-year Comparative Study of Prescriptions of Benzodiazepines and Selective Serotonin Reuptake Inhibitors and Related Drugs in a Japanese University Hospital.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Article
- Anticholinergic burden in community-dwelling older adults: prevalence, associated factors, and agreement between measurement scales.Frontiers in pharmacology · 2026Article
- Benzodiazepine Misuse Among Health Care Workers: The Effect of Sleep Disorders on Work Performance.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benzodiazepines are among the most widely prescribed treatments for insomnia, and can have positive effects on sleep when used for a maximum of 4 weeks. However, benzodiazepines disrupt sleep architecture, and their long-term use leads to negative outcomes, including impairments in memory and attention, increased risk of falls (particularly in the elderly) and car accidents, dependence, and addiction. In addition, stopping benzodiazepines after long-term use can result in severe withdrawal symptoms. Spain is one of the countries with the most widespread benzodiazepine use. A multidisciplinary approach is crucial for the treatment of insomnia and for preventing benzodiazepine overuse/misuse. The present study provides an updated overview of the epidemiology and use of these drugs in vulnerable populations (adolescents, older adults and people with mental disorders). We also describe deprescribing strategies used in clinical practice and present two case studies to exemplify the complexities of benzodiazepine withdrawal observed in our practice. Finally, proposals are provided for the rational use of benzodiazepines in Spain, targeted to the general population, healthcare professionals, and regulatory authorities, in order to improve the clinical management of insomnia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.